Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2011 - 20173

Settings

Has files: YesSubject: search.filters.subject.Metformin

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Metformin Decreases Thyroid Volume and Nodule Size in Subjects with Insulin Resistance: A Preliminary Study
    (2016) Anil, Cuneyd; Kut, Altug; Atesagaoglu, Berna; Nar, Asli; Tutuncu, Neslihan Bascil; Gursoy, Alptekin; 26618447
    Objective: The aim of this study was to investigate the effects of metformin on thyroid volume and nodule size. Subjects and Methods: Prospective data were gathered on 100 newly diagnosed subjects with insulin resistance (68 female, 32 male) between August 2008 and May 2010. Each subject followed a standard diet and exercise program, and received 1,700 mg/day of metformin therapy for 6 months. The height, weight, waist circumference (WC) and thyroid hormone levels of each subject were measured. Additionally, the dimensions of the thyroid lobes and maximum diameter of each thyroid nodule were determined by ultrasonography. BMI and thyroid volumes were also calculated. Insulin resistance was estimated by homeostasis model assessment. All these parameters were measured at the beginning and at the end of the treatment period. Results: BMI and WC decreased significantly after metformin therapy (34.5 +/- 5.1 vs. 32.7 +/- 4.8, p < 0.0001, and 106.3 +/- 11.8 vs. 101.8 +/- 19.0 cm, p = 0.008, respectively). Insulin resistance also decreased after metformin therapy (4.5 +/- 1.9 vs. 2.9 +/- 1.7, p < 0.0001). The mean thyroid volume (22.5 +/- 11.2 vs. 20.3 +/- 10.4 ml, p < 0.0001) and mean thyroid nodule size (12.9 +/- 7.6 vs. 11.7 +/- 7.2 mm, p < 0.0001) also decreased after treatment. Conclusion: In subjects with insulin resistance, metformin therapy significantly decreased thyroid volume and nodule size. (C) 2015 S. Karger AG, Basel
  • Thumbnail Image
    Item
    Metformin: Hype or Hope for Cancer
    (2017) Nar, Asli; 0000-0003-0998-8388; AAA-2743-2021
    Current studies show that especially pancreatic, liver, endometrial, colorectal, bladder and breast cancer incidences are increased by the presence of type 2 diabetes mellitus (T2DM). Possible links between T2DM and cancer include hyperinsulinemia, dysregulation of adipocytokines and hyperglycemia as well as shared confounding risk factors. There is evidence emerging from experimental and clinical studies that metformin can play a crucial anti-cancereous role. Since 2005, multiple studies showed the association between metformin and the reduction of risk in cancers of pancreas, colorectal, stomach, liver, breast and esophagus in diabetes cases. It was also claimed to improve survival in some cancers. Metformin is an insulin sensitizer and mainly acts through inhibiting hepatic gluconeogenesis by activating LKB1/AMP-activated protein kinase (AMPK). Metformin was found to have anti-cancerous and anti-metastatic effects mainly through activating AMPK dependent and independent signaling; inhibiting mTOR, MAPK, HER2, NF-kappa B, IGF signaling pathways and with its possible immuno-modulatory effects. Further studies are needed to evaluate the potential of metformin as adjuvant therapy for cancer especially in non-diabetic patients.
  • No Thumbnail Available
    Item
    Metformin kullanımının tiroid volüm ve fonksiyonlarına etkisi
    (Başkent Üniversitesi Tıp Fakültesi, 2011) Ateşağaoğlu, Berna; Nar, Aslı
    İnsülin direnci ve ilişkili metabolik bozuklukların tiroid bezinde ortaya çıkardığı fonksiyonel ve morfolojik değişiklikler son dönemin sıcak gündemini oluşturmaktadır. Önceki çalışmalarda insülin direnci (ID) olan hastalarda tiroid hacmi ve nodül prevelansının artmış olduğu gösterilmiştir. Bu çalışmada metforminin tiroid hacmi ve nodül boyutu üzerine etkilerini araştırdık. ID olan yeni tanı almış obez hastalar (n: 100; 68 kadın, 32 erkek) Ağustos 2008 ile Mayıs 2010 arasında prospektif olarak takip edildi. Tüm katılımcılara metformin tedavisinden önce ve 6 ay sonra serum TSH, serbest T3, serbest T4 ve tiroid ultrasonografisi yapıldı. Metformin tedavisinden sonra ortalama vücut kitle indeksi (VKİ) ve bel çevresi (BÇ) anlamlı ölçüde azalmıştır (34.5 ± 5.1 kg/m2 iken 32.7 ± 4.8 kg/m2 ve 106.3 ± 11.8 cm iken 101.8 ± 19.0 cm, sırası ile) (BMI için P < 0.0001 ve BÇ için P = 0.008). Hemostaz model değerlendirmesi ile bulunan ID de metformin tedavisi ile azalmıştır (4.5 ± 1.9 iken 2.9 ± 1.7, P < 0.0001). Tedavi sonrası ortalama TSH düzeyi azalmış (1.8 ± 1.0 mIU/L iken 1.5 ± 0.8 mIU/L, P < 0.0001), ortalama serbest T3 yükselmiş (2.7 ± 0.7 pg/mL iken 3.0 ± 0.8 pg/mL, P = 0.03), ve ortalama serbest T4 benzer bulunmuştur (1.4 ± 0.6 ng/dL iken 1.5 ± 1.3 ng/dL, P > 0.5). Ortalama tiroid hacmi (22.5 ± 11.2 mL iken 20.3 ± 10.4 mL, P < 0.0001) ve ortalama tiroid nodül boyutu (12.9 ± 7.6 mm iken 11.7 ± 7.2 mm, P < 0.0001) da tedavi sonrası azalmıştır. Cinsiyetin klinik göstergelerdeki değişim üzerinde istatistiksel olarak anlamlı etkisi yoktu (p>0,05) . Yaşın ise sadece volüm değişimi üzerinde anlamlı etkisi olup 50 yaş üstü grubunda volüm daha fazla azalmıştı (22,4 ±11,1 mL iken 20,2±10,4 mL, p=0,006). Sonuçlar, ID olan hastalarda metformin tedavisinin tiroid hacmini ve nodül boyutunu anlamlı olarak azalttığını göstermektedir.